Indaptus Therapeutics, Inc. — Director's Dealing 2021

Aug 2, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Intec Parent Inc. (NTEC)
CIK: 0001857044
Period of Report: 2021-07-23

Reporting Person: Sassi Nir (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$331.2	2026-03-27	Common Stock (41)		Direct
Stock Option (right to buy)	$357.3	2026-07-25	Common Stock (500)		Direct
Stock Option (right to buy)	$436.8	2024-07-05	Common Stock (625)		Direct
Stock Option (right to buy)	$415.2	2025-01-02	Common Stock (625)		Direct
Stock Option (right to buy)	$610.2	2026-01-22	Common Stock (1125)		Direct
Stock Option (right to buy)	$72	2026-09-13	Common Stock (2500)		Direct
Stock Option (right to buy)	$34.3	2027-02-17	Common Stock (1125)		Direct
Stock Option (right to buy)	$25.7	2027-09-16	Common Stock (1250)		Direct
Stock Option (right to buy)	$357.3	2026-07-25	Common Stock (500)		Direct

Footnotes

F1: The stock options are fully vested and are exercisable.

F2: The options vest and become exercisable as to one-third of the total shares on January 22, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through January 22, 2022.

F3: The options vest and become exercisable as to one-third of the total shares on September 13, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through September 13, 2022.

F4: The options vest and become exercisable as to one-third of the total shares on February 17, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through February 17, 2023.

F5: The options vest and become exercisable in full on December 31, 2021.

F6: The options become fully vested only in the event that a material agreement is entered into between the Company and a third party.